Private Advisor Group LLC Acquires Shares of 14,150 Apellis Pharmaceuticals Inc (APLS)

Share on StockTwits

Private Advisor Group LLC acquired a new position in shares of Apellis Pharmaceuticals Inc (NASDAQ:APLS) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 14,150 shares of the company’s stock, valued at approximately $187,000.

Other hedge funds also recently added to or reduced their stakes in the company. Sphera Funds Management LTD. raised its holdings in Apellis Pharmaceuticals by 91.8% during the third quarter. Sphera Funds Management LTD. now owns 212,470 shares of the company’s stock worth $3,778,000 after purchasing an additional 101,667 shares in the last quarter. Opaleye Management Inc. raised its holdings in Apellis Pharmaceuticals by 41.5% during the third quarter. Opaleye Management Inc. now owns 375,000 shares of the company’s stock worth $6,667,000 after purchasing an additional 110,000 shares in the last quarter. Virtu Financial LLC acquired a new position in shares of Apellis Pharmaceuticals in the 3rd quarter valued at $283,000. Prudential Financial Inc. increased its holdings in shares of Apellis Pharmaceuticals by 36.5% in the 3rd quarter. Prudential Financial Inc. now owns 184,130 shares of the company’s stock valued at $3,274,000 after acquiring an additional 49,230 shares during the period. Finally, MetLife Investment Advisors LLC acquired a new position in shares of Apellis Pharmaceuticals in the 3rd quarter valued at $477,000. 53.89% of the stock is currently owned by institutional investors.

In other Apellis Pharmaceuticals news, major shareholder Morningside Venture Investment bought 441,176 shares of the business’s stock in a transaction dated Monday, March 11th. The shares were acquired at an average cost of $17.00 per share, with a total value of $7,499,992.00. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders own 9.30% of the company’s stock.

Shares of Apellis Pharmaceuticals stock opened at $14.00 on Friday. The firm has a market capitalization of $884.65 million, a PE ratio of -3.80 and a beta of 0.37. Apellis Pharmaceuticals Inc has a 12 month low of $11.45 and a 12 month high of $32.00. The company has a debt-to-equity ratio of 0.16, a quick ratio of 11.89 and a current ratio of 11.89.

A number of equities analysts have recently commented on APLS shares. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $53.00 target price on shares of Apellis Pharmaceuticals in a report on Thursday, December 20th. Citigroup lifted their target price on shares of Apellis Pharmaceuticals from $34.00 to $40.00 and gave the company a “buy” rating in a report on Thursday, December 6th. B. Riley started coverage on shares of Apellis Pharmaceuticals in a report on Tuesday, January 8th. They issued a “buy” rating and a $40.00 target price on the stock. Zacks Investment Research raised shares of Apellis Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Monday, March 4th. Finally, JPMorgan Chase & Co. cut shares of Apellis Pharmaceuticals from an “overweight” rating to a “neutral” rating and set a $34.00 target price on the stock. in a report on Wednesday, January 23rd. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $39.33.

TRADEMARK VIOLATION NOTICE: “Private Advisor Group LLC Acquires Shares of 14,150 Apellis Pharmaceuticals Inc (APLS)” was first posted by Week Herald and is the property of of Week Herald. If you are viewing this piece on another website, it was illegally stolen and reposted in violation of U.S. & international copyright legislation. The original version of this piece can be viewed at https://weekherald.com/2019/03/17/private-advisor-group-llc-acquires-shares-of-14150-apellis-pharmaceuticals-inc-apls.html.

Apellis Pharmaceuticals Profile

Apellis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutic compounds for autoimmune and inflammatory diseases. Its lead product candidate is APL-2 to treat geographic atrophy, wet age-related macular degeneration, paroxysmal nocturnal hemoglobinuria, autoimmune hemolytic anemia, and nephrology.

Recommended Story: Momentum Investing

Want to see what other hedge funds are holding APLS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Apellis Pharmaceuticals Inc (NASDAQ:APLS).

Institutional Ownership by Quarter for Apellis Pharmaceuticals (NASDAQ:APLS)

Receive News & Ratings for Apellis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apellis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.